切换至 "中华医学电子期刊资源库"

中华腔镜泌尿外科杂志(电子版) ›› 2019, Vol. 13 ›› Issue (03) : 166 -169. doi: 10.3877/cma.j.issn.1674-3253.2019.03.006

所属专题: 文献

临床研究

联合检测尿液中Survivin和MUC7在膀胱癌诊断中的临床应用
林祯祥1, 蒲小勇2,(), 刘久敏2, 毕学成2, 李腾2, 方建雄2, 张协武2   
  1. 1. 510515 广州,南方医科大学
    2. 510080 广州,广东省人民医院泌尿外科,广东省医学科学院
  • 收稿日期:2019-02-02 出版日期:2019-06-01
  • 通信作者: 蒲小勇
  • 基金资助:
    广州市科技计划项目(2014J4100041); 国家卫生和计划生育委员会男性生殖与遗传重点实验室课题资助项目(KF201801); 广东省人民医院科研项目(Y012012012)

Clinical significance of combined detection of Survivin and MUC7 in urine in the detection of bladder cancer

Zhenxiang Lin1, Xiaoyong Pu2,(), Jiumin Liu2, Xuecheng Bi2, Teng Li2, Jianxiong Fang2, Xiewu Zhang2   

  1. 1. The Southern Medical University, Guangzhou 510515, China
    2. Department of Urology, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Guangzhou 510000, China
  • Received:2019-02-02 Published:2019-06-01
  • Corresponding author: Xiaoyong Pu
  • About author:
    Corresponding author: Pu Xiaoyong, Email:
引用本文:

林祯祥, 蒲小勇, 刘久敏, 毕学成, 李腾, 方建雄, 张协武. 联合检测尿液中Survivin和MUC7在膀胱癌诊断中的临床应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2019, 13(03): 166-169.

Zhenxiang Lin, Xiaoyong Pu, Jiumin Liu, Xuecheng Bi, Teng Li, Jianxiong Fang, Xiewu Zhang. Clinical significance of combined detection of Survivin and MUC7 in urine in the detection of bladder cancer[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2019, 13(03): 166-169.

目的

探讨检测尿液中Survivin和mucin 7(MUC7)在诊断膀胱癌中的临床价值。

方法

对75例膀胱肿瘤患者、38例泌尿系统良性疾病患者及20例健康自愿者在行膀胱镜检前分别留置3份尿液标本,通过检测尿液中Survivin、MUC7和尿脱落细胞学的敏感性和特异性,分析比较3种方法在临床诊断膀胱癌的临床应用价值。

结果

Survivin诊断膀胱癌的敏感性和特异性分别是93.3%和98.3%,MUC7诊断膀胱癌的敏感性和特异性分别是80%和100%;尿脱落细胞学诊断膀胱癌的敏感性和特异性分别是66.7%和100%;Survivin联合MUC7的敏感性和特异性分别是98.7%和100%;Survivin联合MUC7、Survivin、MUC7与尿脱落细胞学的敏感性比较差异均有统计学意义(P<0.05)。Survivin联合MUC7、Survivin、MUC7与尿脱落细胞细胞学的准确性分别是99.2%、95.5%、88.7%、81.2.3%,与脱落细胞学组比较,差异有统计学意义(P<0.05)。

结论

联合检测两种肿瘤标记物Survivin及MUC7可以提高膀胱癌诊断的敏感性和准确性。

Objective

To investigate the clinical value of detection of Survivin and mucin 7 (MUC7) in urine in the diagnosis of bladder cancer.

Methods

Seventy-five patients with bladder cancer, 38 patients with benign diseases of urinary system and 20 healthy volunteers were enrolled, and three urine specimens were collected in all patients. The clinical value of three methods in the diagnosis of bladder cancer was analyzed and compared by detecting the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of Survivin, MUC7 and cytology in urine respectively.

Results

The sensitivity and specificity of Survivin in the diagnosis of bladder cancer were 93.3% and 98.3%, respectively. The sensitivity and specificity of MUC7 in the diagnosis of bladder cancer were 80% and 100%, respectively. The sensitivity and specificity of cytology in the diagnosis of bladder cancer were 66.7% and 100%, respectively. The sensitivity and specificity of Survivin combined with MUC7 were 98.7% and 100%, respectively. The significant differences were observed in the sensitivity when comparing Survivin or MUC7 with the cytology respectively (P<0.05). The accuracy of Survivin combined with MUC7, Survivin MUC7 and cytology were 99.2%, 95.5%, 88.7% and 81.2.3%, respectively, which had obviously increasement compared with cytology group (78.3%) (P<0.05, respectively).

Conclusions

Combination of Survivin and MUC7 can improve the sensitivity and accuracy in diagnosis of bladder cancer.

表1 尿脱落细胞学与Survivin及MUC7敏感性的比较[例(%)]
表2 三种方法的敏感性、特异性、阳性预测值、阴性预测值和准确性比较[例(%)]
表3 MUC7和Survivin在不同膀胱肿瘤分级及分期中敏感性的比较[例(%)]
[1]
Apollo A, Ortenzi V, Scatena C, et al. Molecular characterization of low grade and high grade bladder cancer[J]. PLoS One. 2019, 14(1): e0210635.
[2]
钟文文,胡成,李科, 等. 原位膀胱癌动物模型的建立及其体外活体成像检测[J/CD].中华腔镜泌尿外科杂志(电子版), 2016, 10(4): 56-59.
[3]
谢伟槟,刘皓,孔坚秋, 等. 膀胱癌盆腔淋巴结转移的规律及影响因素分析[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(6): 397-401.
[4]
何威,徐兆平,谢欣,等. 机器人根治性膀胱切除术加双U原位膀胱术治疗肌层浸润性膀胱癌 [J/CD]. 中华腔镜泌尿外科杂志(电子版), 2016, 12(6): 15-18.
[5]
Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics [J]. CA Cancer J Clin, 2001, 51(1): 15-36.
[6]
Pu XY, Wang ZP, Chen YR, et al. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine [J]. J Cancer Res Clin Oncol, 2008, 134(6): 659-665.
[7]
March-Villalba JA, Ramos-Soler D, Soriano-Sarrió P, et al. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973) [J]. Urol Oncol, 2019 , 37(2): 158-165.
[8]
Moussa O, Abol-Enein H, Bissada N K, et al. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer [J]. J Urol, 2006, 175(6): 2312-2316.
[9]
Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer [J]. JAMA, 2001, 285 (3): 324-328.
[10]
廖洪,唐国民,张荣荣, 等. 膀胱移行细胞癌患者尿脱落细胞中MUC7和CK20的表达及其临床意义[J]. 四川医学, 2006, 27(6): 558-560.
[11]
Retz M, Lehmann J, Roder C, et al. Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma [J]. Cancer Res, 1998, 58(24): 5662-5666.
[12]
Ku JH, Godoy G, Amiel GE, et al. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review[J]. BJU Int, 2012, 110(5): 630-636.
[13]
Wang H, Xi X, Kong X, et al. The expression and significance of survivin mRNA in urinary bladder carcinomas [J]. J Cancer Res Clin Oncol, 2004, 130(8): 487-490.
[14]
Muhammad AS, Mungadi IA, Ndodu ED, et al. Performance of urinary survivin as a non-invasive molecular marker of bladdercarcinoma ina schistosomiasis endemic area [J]. Ghana Med J, 2018, 52(2): 74-78.
[15]
Okegawa T, Kinjo M, Horie S, et al. Detection of mucin 7 gene expression in efoliated cells in urine from patients with bladder tumor [J]. Urology, 2003, 62(1): 182-186.
[16]
Kinjo M, Okegawa T, Horie S, et al. Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients [J]. Int J Urol. 2004, 11(1): 38-43.
[1] 曹雯佳, 刘学兵, 罗安果, 钟释敏, 邓岚, 王玉琳, 李赵欢. 超声矢量血流成像对2型糖尿病患者颈动脉壁剪切应力的研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 709-717.
[2] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[3] 徐志刚, 曹涛, 何亭, 李博奥, 魏婧韬, 张栋梁, 官浩, 杨薛康. 采用抗生素骨水泥治疗糖尿病患者心脏术后胸骨骨髓炎的临床效果观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 498-502.
[4] 孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[5] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[6] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[7] 刘柏隆, 周祥福. 女性尿失禁吊带手术并发症处理的经验分享[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 127-127.
[8] 薛庆, 施赛叶, 徐雅文, 盛夏, 张芹芹. 追踪方法学联合失效模式与效应分析在膀胱灌注化疗患者中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 553-559.
[9] 吴春风, 卢国汉, 姚汝贺, 李健辉, 陈文杰, 黄宇. 21 F膀胱镜鞘联合8.0/9.8 F输尿管镜与等离子电切镜在膀胱结石钬激光碎石术中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 579-584.
[10] 黄俊龙, 李文双, 李晓阳, 刘柏隆, 陈逸龙, 丘惠平, 周祥福. 基于盆底彩超的人工智能模型在女性压力性尿失禁分度诊断中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 597-605.
[11] 屈勤芳, 束方莲. 盆腔器官脱垂患者盆底重建手术后压力性尿失禁发生的影响因素及列线图预测模型构建[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 606-612.
[12] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[13] 周学锋, 董哲毅, 冯哲, 蔡广研, 陈香美. 糖尿病肾脏疾病中西医结合诊疗指南计划书[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 301-305.
[14] 杜军霞, 赵小淋, 王浩然, 高志远, 王曼茜, 万楠熙, 张冬, 丁潇楠, 任琴琴, 段颖洁, 汤力, 朱晗玉. 2 型糖尿病的血液透析患者肠道微生物组学高通量测序分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 313-320.
[15] 倪颖, 张铁龙, 王岗, 高玉龙, 陈韶鹏, 倪家璇. 未预置支架逆行输尿管镜治疗近端输尿管结石手术中的困难与应对[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 795-801.
阅读次数
全文


摘要